Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 3
2015 2
2016 3
2017 6
2018 5
2019 5
2020 15
2021 8
2022 5
2023 4
2024 18
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

61 results

Results by year

Filters applied: . Clear all
Page 1
Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors.
Basu S, Parghane RV, Kamaldeep, Chakrabarty S. Basu S, et al. Among authors: parghane rv. Semin Nucl Med. 2020 Sep;50(5):447-464. doi: 10.1053/j.semnuclmed.2020.05.004. Epub 2020 Jul 3. Semin Nucl Med. 2020. PMID: 32768008 Review.
One decade of 'Bench-to-Bedside' peptide receptor radionuclide therapy with indigenous [177Lu]Lu-DOTATATE obtained through 'Direct' neutron activation route: lessons learnt including practice evolution in an Indian setting.
Basu S, Chakraborty S, Parghane RV, Kamaldeep, Ranade R, Thapa P, Asopa RV, Sonawane G, Nabar S, Shimpi H, Chandak A, Vimalnath KV, Ostwal V, Ramaswamy A, Bhandare M, Chaudhari V, Shrikhande SV, Sirohi B, Dash A, Banerjee S. Basu S, et al. Among authors: parghane rv. Am J Nucl Med Mol Imaging. 2020 Aug 25;10(4):178-211. eCollection 2020. Am J Nucl Med Mol Imaging. 2020. PMID: 32929396 Free PMC article. Review.
Towards personalizing treatment strategies in mCRPC: can dual-tracer PET-CT provide insights into tumor biology, guide the optimal treatment sequence, and individualize decision-making (between chemotherapy, second-generation anti-androgens and PSMA-directed radioligand therapy) early in the disease course?
Basu S, Parghane RV, Suman S, Joshi A, Prabhash K, Bakshi G, Banerjee S. Basu S, et al. Among authors: parghane rv. Eur J Nucl Med Mol Imaging. 2020 Jul;47(8):1793-1797. doi: 10.1007/s00259-019-04616-w. Eur J Nucl Med Mol Imaging. 2020. PMID: 31776630 No abstract available.
61 results